SU5416, a VEGF Receptor Inhibitor and Ligand of the AHR, Represents a New Alternative for Immunomodulation

The experimental compound SU5416 went as far as Phase III clinical trials as an anticancer agent, putatively because of its activity as a VEGFR-2 inhibitor, but showed poor results. Here, we show that SU5416 is also an aryl hydrocarbon receptor (AHR) agonist with unique properties. Like TCDD, SU5416...

Descripción completa

Detalles Bibliográficos
Autores principales: Mezrich, Joshua D., Nguyen, Linh P., Kennedy, Greg, Nukaya, Manabu, Fechner, John H., Zhang, Xiaoji, Xing, Yongna, Bradfield, Christopher A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3435281/
https://www.ncbi.nlm.nih.gov/pubmed/22970246
http://dx.doi.org/10.1371/journal.pone.0044547

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3435281/
https://www.ncbi.nlm.nih.gov/pubmed/22970246
http://dx.doi.org/10.1371/journal.pone.0044547

Ejemplares similares